ID   PLPL2_HUMAN             Reviewed;         504 AA.
AC   Q96AD5; O60643; Q5EFF5; Q6XYE5; Q96ET6; Q9NQ61; Q9NQ62;
DT   26-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 122.
DE   RecName: Full=Patatin-like phospholipase domain-containing protein 2;
DE            EC=3.1.1.3;
DE   AltName: Full=Adipose triglyceride lipase;
DE   AltName: Full=Calcium-independent phospholipase A2;
DE   AltName: Full=Desnutrin;
DE   AltName: Full=IPLA2-zeta;
DE   AltName: Full=Pigment epithelium-derived factor;
DE   AltName: Full=TTS2.2;
DE   AltName: Full=Transport-secretion protein 2;
DE            Short=TTS2;
GN   Name=PNPLA2; Synonyms=ATGL; ORFNames=FP17548;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=15550674; DOI=10.1126/science.1100747;
RA   Zimmermann R., Strauss J.G., Haemmerle G., Schoiswohl G.,
RA   Birner-Gruenberger R., Riederer M., Lass A., Neuberger G.,
RA   Eisenhaber F., Hermetter A., Zechner R.;
RT   "Fat mobilization in adipose tissue is promoted by adipose
RT   triglyceride lipase.";
RL   Science 306:1383-1386(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT PRO-481.
RA   Strahl T., Shingler W.H., Lammiman M., Gregory C.D., Leach L.,
RA   Matthias P., Nielsen P.J., Shaw P.E.;
RT   "TTS-2, a novel protein implicated in vesicular transport of the cell
RT   surface receptor ICAM-3.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H.,
RA   Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y.,
RA   Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S.,
RA   Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-481.
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 94-504 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=15364929; DOI=10.1074/jbc.M407841200;
RA   Jenkins C.M., Mancuso D.J., Yan W., Sims H.F., Gibson B., Gross R.W.;
RT   "Identification, cloning, expression, and purification of three novel
RT   human calcium-independent phospholipase A2 family members possessing
RT   triacylglycerol lipase and acylglycerol transacylase activities.";
RL   J. Biol. Chem. 279:48968-48975(2004).
RN   [7]
RP   DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RX   PubMed=16249444; DOI=10.2337/diabetes.54.11.3190;
RA   Langin D., Dicker A., Tavernier G., Hoffstedt J., Mairal A., Ryden M.,
RA   Arner E., Sicard A., Jenkins C.M., Viguerie N., van Harmelen V.,
RA   Gross R.W., Holm C., Arner P.;
RT   "Adipocyte lipases and defect of lipolysis in human obesity.";
RL   Diabetes 54:3190-3197(2005).
RN   [8]
RP   TISSUE SPECIFICITY, AND MUTAGENESIS OF SER-47.
RX   PubMed=16150821; DOI=10.1194/jlr.M500290-JLR200;
RA   Lake A.C., Sun Y., Li J.-L., Kim J.E., Johnson J.W., Li D., Revett T.,
RA   Shih H.H., Liu W., Paulsen J.E., Gimeno R.E.;
RT   "Expression, regulation, and triglyceride hydrolase activity of
RT   Adiponutrin family members.";
RL   J. Lipid Res. 46:2477-2487(2005).
RN   [9]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=16705060; DOI=10.1152/ajpendo.00317.2005;
RA   Kim J.Y., Tillison K., Lee J.-H., Rearick D.A., Smas C.M.;
RT   "The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated
RT   by insulin and TNF-alpha in 3T3-L1 adipocytes and is a target for
RT   transactivation by PPARgamma.";
RL   Am. J. Physiol. 291:E115-E127(2006).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-47.
RX   PubMed=16239926; DOI=10.1038/sj.embor.7400559;
RA   Smirnova E., Goldberg E.B., Makarova K.S., Lin L., Brown W.J.,
RA   Jackson C.L.;
RT   "ATGL has a key role in lipid droplet/adiposome degradation in
RT   mammalian cells.";
RL   EMBO Rep. 7:106-113(2006).
RN   [11]
RP   ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION WITH
RP   SERPINF1, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL
RP   STAGE.
RX   PubMed=17032652; DOI=10.1074/jbc.M600353200;
RA   Notari L., Baladron V., Aroca-Aguilar J.D., Balko N., Heredia R.,
RA   Meyer C., Notario P.M., Saravanamuthu S., Nueda M.-L.,
RA   Sanchez-Sanchez F., Escribano J., Laborda J., Becerra S.P.;
RT   "Identification of a lipase-linked cell membrane receptor for pigment
RT   epithelium-derived factor.";
RL   J. Biol. Chem. 281:38022-38037(2006).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   PHOSPHORYLATION AT SER-404.
RX   PubMed=22733971; DOI=10.1210/en.2012-1127;
RA   Pagnon J., Matzaris M., Stark R., Meex R.C., Macaulay S.L., Brown W.,
RA   O'Brien P.E., Tiganis T., Watt M.J.;
RT   "Identification and functional characterization of protein kinase A
RT   phosphorylation sites in the major lipolytic protein, adipose
RT   triglyceride lipase.";
RL   Endocrinology 153:4278-4289(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-404 AND SER-428, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   INTERACTION WITH FAF2.
RX   PubMed=23297223; DOI=10.1073/pnas.1213738110;
RA   Olzmann J.A., Richter C.M., Kopito R.R.;
RT   "Spatial regulation of UBXD8 and p97/VCP controls ATGL-mediated lipid
RT   droplet turnover.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1345-1350(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   PHOSPHORYLATION AT SER-404.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [19]
RP   VARIANTS PHE-219; LYS-252 AND PRO-481, POLYMORPHISM, AND ASSOCIATION
RP   WITH DIABETES MELLITUS TYPE 2.
RX   PubMed=16644682; DOI=10.2337/db05-1498;
RA   Schoenborn V., Heid I.M., Vollmert C., Lingenhel A., Adams T.D.,
RA   Hopkins P.N., Illig T., Zimmermann R., Zechner R., Hunt S.C.,
RA   Kronenberg F.;
RT   "The ATGL gene is associated with free fatty acids, triglycerides, and
RT   type 2 diabetes.";
RL   Diabetes 55:1270-1275(2006).
RN   [20]
RP   VARIANT NLSDM LEU-195.
RX   PubMed=17187067; DOI=10.1038/ng1951;
RA   Fischer J., Lefevre C., Morava E., Mussini J.-M., Laforet P.,
RA   Negre-Salvayre A., Lathrop M., Salvayre R.;
RT   "The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in
RT   neutral lipid storage disease with myopathy.";
RL   Nat. Genet. 39:28-30(2007).
CC   -!- FUNCTION: Catalyzes the initial step in triglyceride hydrolysis in
CC       adipocyte and non-adipocyte lipid droplets (PubMed:15550674). Also
CC       has acylglycerol transacylase activity. May act coordinately with
CC       LIPE/HLS within the lipolytic cascade. Regulates adiposome size
CC       and may be involved in the degradation of adiposomes
CC       (PubMed:16239926). May play an important role in energy
CC       homeostasis. May play a role in the response of the organism to
CC       starvation, enhancing hydrolysis of triglycerides and providing
CC       free fatty acids to other tissues to be oxidized in situations of
CC       energy depletion. {ECO:0000269|PubMed:15364929,
CC       ECO:0000269|PubMed:15550674, ECO:0000269|PubMed:16239926}.
CC   -!- CATALYTIC ACTIVITY: Triacylglycerol + H(2)O = diacylglycerol + a
CC       carboxylate.
CC   -!- ENZYME REGULATION: Inhibited by BEL ((E)-6-(bromomethylene)-3-(1-
CC       naphthalenyl)-2H-tetrahydropyran-2-one), a suicide substrate
CC       inhibitor. No differences in enzymatic activity that uses (1,2-
CC       dilinoleoyl)-phosphatidylcholine as substrate was detected in the
CC       presence or absence of ATP. Activated by ABHD5 and SERPINF1.
CC       {ECO:0000269|PubMed:15364929, ECO:0000269|PubMed:17032652}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 7.5 with (1,2-dilinoleoyl)-phosphatidylcholine as
CC         substrate. {ECO:0000269|PubMed:17032652};
CC   -!- PATHWAY: Glycerolipid metabolism; triacylglycerol degradation.
CC   -!- SUBUNIT: Interacts with ABHD5; this association stimulates PNPLA2
CC       triglyceride hydrolase activity (By similarity). Interacts with
CC       SERPINF1; interacts at one site of interaction. Despite a
CC       colocalization in lipid droplets, it probably does not interact
CC       with PLIN (By similarity). Interacts with PLIN5; prevents
CC       interaction with ABHD5 (By similarity). Interacts with FAF2
CC       (PubMed:23297223). {ECO:0000250|UniProtKB:Q8BJ56,
CC       ECO:0000269|PubMed:23297223}.
CC   -!- SUBCELLULAR LOCATION: Lipid droplet. Cell membrane; Single-pass
CC       type II membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96AD5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96AD5-2; Sequence=VSP_026421;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highest expression in adipose tissue. Also
CC       detected in heart, skeletal muscle, and portions of the
CC       gastrointestinal tract. Detected in normal retina and
CC       retinoblastoma cells. Detected in retinal pigment epithelium and,
CC       at lower intensity, in the inner segments of photoreceptors and in
CC       the ganglion cell layer of the neural retina (at protein level).
CC       {ECO:0000269|PubMed:15550674, ECO:0000269|PubMed:16150821,
CC       ECO:0000269|PubMed:16249444, ECO:0000269|PubMed:17032652}.
CC   -!- DEVELOPMENTAL STAGE: Induced during differentiation of primary
CC       preadipocytes to adipocytes. Expression increased from fetal to
CC       adult in retinal pigment epithelium. {ECO:0000269|PubMed:16249444,
CC       ECO:0000269|PubMed:16705060, ECO:0000269|PubMed:17032652}.
CC   -!- PTM: Phosphorylation at Ser-404 by PKA is increased during fasting
CC       and moderate intensity exercise, and moderately increases
CC       lipolytic activity (By similarity). Phosphorylation at Ser-404 is
CC       increased upon beta-adrenergic stimulation. {ECO:0000250,
CC       ECO:0000269|PubMed:22733971}.
CC   -!- POLYMORPHISM: Genetic variations in PNPLA2 may influence plasma
CC       free fatty acids and triglycerides levels, and fasting glucose
CC       concentrations. {ECO:0000269|PubMed:16644682}.
CC   -!- DISEASE: Note=Genetic variations in PNPLA2 may be associated with
CC       risk of diabetes mellitus type 2. {ECO:0000269|PubMed:16644682}.
CC   -!- DISEASE: Neutral lipid storage disease with myopathy (NLSDM)
CC       [MIM:610717]: Neutral lipid storage disorder (NLSD) with myopathy
CC       but without ichthyosis. NLSDs are characterized by the presence of
CC       triglyceride-containing cytoplasmic droplets in leukocytes and in
CC       other tissues, including bone marrow, skin, and muscle.
CC       Individuals with NLSDM did not show obesity, in spite of a defect
CC       in triglyceride degradation in fibroblasts and in marked
CC       triglyceride storage in liver, muscles, and other visceral cells.
CC       {ECO:0000269|PubMed:17187067}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP34448.1; Type=Frameshift; Positions=501; Evidence={ECO:0000305};
CC       Sequence=CAC01131.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAC01132.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY894804; AAW81962.1; -; mRNA.
DR   EMBL; AJ278475; CAC01131.1; ALT_INIT; mRNA.
DR   EMBL; AJ278476; CAC01132.1; ALT_INIT; mRNA.
DR   EMBL; AY203925; AAP34448.1; ALT_FRAME; mRNA.
DR   EMBL; BC011958; AAH11958.1; -; mRNA.
DR   EMBL; BC017280; AAH17280.1; -; mRNA.
DR   EMBL; AF055000; AAC09354.1; -; mRNA.
DR   CCDS; CCDS7718.1; -. [Q96AD5-1]
DR   RefSeq; NP_065109.1; NM_020376.3. [Q96AD5-1]
DR   RefSeq; XP_016873517.1; XM_017018028.1. [Q96AD5-1]
DR   UniGene; Hs.654697; -.
DR   ProteinModelPortal; Q96AD5; -.
DR   SMR; Q96AD5; -.
DR   BioGrid; 121370; 16.
DR   IntAct; Q96AD5; 12.
DR   MINT; MINT-1184430; -.
DR   STRING; 9606.ENSP00000337701; -.
DR   SwissLipids; SLP:000000311; -.
DR   iPTMnet; Q96AD5; -.
DR   PhosphoSitePlus; Q96AD5; -.
DR   BioMuta; PNPLA2; -.
DR   DMDM; 74731110; -.
DR   EPD; Q96AD5; -.
DR   MaxQB; Q96AD5; -.
DR   PaxDb; Q96AD5; -.
DR   PeptideAtlas; Q96AD5; -.
DR   PRIDE; Q96AD5; -.
DR   DNASU; 57104; -.
DR   Ensembl; ENST00000336615; ENSP00000337701; ENSG00000177666. [Q96AD5-1]
DR   GeneID; 57104; -.
DR   KEGG; hsa:57104; -.
DR   UCSC; uc001lrt.4; human. [Q96AD5-1]
DR   CTD; 57104; -.
DR   DisGeNET; 57104; -.
DR   GeneCards; PNPLA2; -.
DR   HGNC; HGNC:30802; PNPLA2.
DR   HPA; HPA055173; -.
DR   HPA; HPA062602; -.
DR   MalaCards; PNPLA2; -.
DR   MIM; 609059; gene.
DR   MIM; 610717; phenotype.
DR   neXtProt; NX_Q96AD5; -.
DR   OpenTargets; ENSG00000177666; -.
DR   Orphanet; 98908; Neutral lipid storage myopathy.
DR   PharmGKB; PA134903083; -.
DR   eggNOG; KOG3773; Eukaryota.
DR   eggNOG; ENOG410XSQS; LUCA.
DR   GeneTree; ENSGT00390000005295; -.
DR   HOVERGEN; HBG007046; -.
DR   InParanoid; Q96AD5; -.
DR   KO; K16816; -.
DR   OMA; DSHEHAS; -.
DR   OrthoDB; EOG091G05MG; -.
DR   PhylomeDB; Q96AD5; -.
DR   TreeFam; TF314272; -.
DR   Reactome; R-HSA-1482883; Acyl chain remodeling of DAG and TAG.
DR   UniPathway; UPA00256; -.
DR   ChiTaRS; PNPLA2; human.
DR   GeneWiki; PNPLA2; -.
DR   GenomeRNAi; 57104; -.
DR   PRO; PR:Q96AD5; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000177666; -.
DR   CleanEx; HS_PNPLA2; -.
DR   Genevisible; Q96AD5; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005811; C:lipid particle; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016411; F:acylglycerol O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0004465; F:lipoprotein lipase activity; TAS:Reactome.
DR   GO; GO:0004806; F:triglyceride lipase activity; ISS:UniProtKB.
DR   GO; GO:0036155; P:acylglycerol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0055088; P:lipid homeostasis; IBA:GO_Central.
DR   GO; GO:0034389; P:lipid particle organization; IEA:Ensembl.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0010891; P:negative regulation of sequestering of triglyceride; IDA:UniProtKB.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IDA:UniProtKB.
DR   GO; GO:0019433; P:triglyceride catabolic process; IEA:UniProtKB-UniPathway.
DR   CDD; cd07220; Pat_PNPLA2; 1.
DR   InterPro; IPR016035; Acyl_Trfase/lysoPLipase.
DR   InterPro; IPR033562; PLPL.
DR   InterPro; IPR033903; PNPLA2.
DR   InterPro; IPR002641; PNPLA_dom.
DR   PANTHER; PTHR12406; PTHR12406; 1.
DR   Pfam; PF01734; Patatin; 1.
DR   SUPFAM; SSF52151; SSF52151; 1.
DR   PROSITE; PS51635; PNPLA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Glycoprotein; Hydrolase; Lipid degradation;
KW   Lipid droplet; Lipid metabolism; Membrane; Phosphoprotein;
KW   Polymorphism; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    504       Patatin-like phospholipase domain-
FT                                containing protein 2.
FT                                /FTId=PRO_0000292527.
FT   TOPO_DOM      1      8       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      9     29       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     30    504       Lumenal. {ECO:0000255}.
FT   DOMAIN       10    179       PNPLA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF        14     19       GXGXXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF        45     49       GXSXG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOTIF       166    168       DGA/G. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE     47     47       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   ACT_SITE    166    166       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01161}.
FT   MOD_RES     372    372       Phosphoserine; in vitro. {ECO:0000250}.
FT   MOD_RES     404    404       Phosphoserine; by PKA and FAM20C.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:22733971,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES     428    428       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     39     39       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1    324       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15498874}.
FT                                /FTId=VSP_026421.
FT   VARIANT     195    195       P -> L (in NLSDM; dbSNP:rs121918259).
FT                                {ECO:0000269|PubMed:17187067}.
FT                                /FTId=VAR_032995.
FT   VARIANT     219    219       L -> F (in dbSNP:rs140612115).
FT                                {ECO:0000269|PubMed:16644682}.
FT                                /FTId=VAR_032996.
FT   VARIANT     252    252       N -> K (in dbSNP:rs140201358).
FT                                {ECO:0000269|PubMed:16644682}.
FT                                /FTId=VAR_032997.
FT   VARIANT     481    481       L -> P (in dbSNP:rs1138693).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:16644682,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_032998.
FT   MUTAGEN      47     47       S->A: Reduces rate of lipid hydrolysis;
FT                                does not affect the localization around
FT                                the rim of the adiposomes.
FT                                {ECO:0000269|PubMed:16150821,
FT                                ECO:0000269|PubMed:16239926}.
FT   CONFLICT    163    163       R -> G (in Ref. 5; AAC09354).
FT                                {ECO:0000305}.
FT   CONFLICT    296    296       I -> V (in Ref. 1; AAW81962).
FT                                {ECO:0000305}.
FT   CONFLICT    333    333       A -> G (in Ref. 3; AAP34448).
FT                                {ECO:0000305}.
FT   CONFLICT    351    351       R -> C (in Ref. 1; AAW81962).
FT                                {ECO:0000305}.
FT   CONFLICT    402    402       V -> L (in Ref. 2; CAC01131/CAC01132).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       L -> P (in Ref. 1; AAW81962).
FT                                {ECO:0000305}.
SQ   SEQUENCE   504 AA;  55316 MW;  D9C16F942AB0B3C7 CRC64;
     MFPREKTWNI SFAGCGFLGV YYVGVASCLR EHAPFLVANA THIYGASAGA LTATALVTGV
     CLGEAGAKFI EVSKEARKRF LGPLHPSFNL VKIIRSFLLK VLPADSHEHA SGRLGISLTR
     VSDGENVIIS HFNSKDELIQ ANVCSGFIPV YCGLIPPSLQ GVRYVDGGIS DNLPLYELKN
     TITVSPFSGE SDICPQDSST NIHELRVTNT SIQFNLRNLY RLSKALFPPE PLVLREMCKQ
     GYRDGLRFLQ RNGLLNRPNP LLALPPARPH GPEDKDQAVE SAQAEDYSQL PGEDHILEHL
     PARLNEALLE ACVEPTDLLT TLSNMLPVRL ATAMMVPYTL PLESALSFTI RLLEWLPDVP
     EDIRWMKEQT GSICQYLVMR AKRKLGRHLP SRLPEQVELR RVQSLPSVPL SCAAYREALP
     GWMRNNLSLG DALAKWEECQ RQLLLGLFCT NVAFPPEALR MRAPADPAPA PADPASPQHQ
     LAGPAPLLST PAPEARPVIG ALGL
//
